MIRIKIZUMAB - A NEW OPTION IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASES

被引：0

作者：

Olszewski, Jakub ^{[1
]}

Kozon, Katarzyna ^{[1
]}

Sitnik, Magdalena ^{[1
]}

Herjan, Katarzyna ^{[2
]}

Mikolap, Karolina ^{[3
]}

Gastol, Bartlomiej ^{[4
]}

Bara, Maciej ^{[5
]}

Armanski, Piotr ^{[6
]}

Sawczuk, Marcin ^{[7
]}

机构：

[1] Masovian Brodnowski Hosp, PL-03242 Warsaw, Poland

[2] Prof W Orlowski Mem Hosp, PL-00401 Warsaw, Poland

[3] Wolski Hosp Warsaw, PL-01211 Warsaw, Poland

[4] Masovian Specialist Hosp Ostroleka, PL-07410 Ostroleka, Poland

[5] Med Univ Warsaw, Infant Jesus Clin Hosp, PL-02005 Warsaw, Poland

[6] Dist Hosp Sochaczew, PL-96500 Sochaczew, Poland

[7] Med Univ Gdansk, Clin Ctr, PL-80952 Gdansk, Poland

来源：

PROSPECTS IN PHARMACEUTICAL SCIENCES | 2024年 / 22卷 / 03期

关键词：

mirikizumab; IL-23; ulcerative colitis; ULCERATIVE-COLITIS; MAINTENANCE THERAPY; INTERLEUKIN-23; DIAGNOSIS; INDUCTION;

D O I：

10.56782/pps.262

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Mirikizumab is a humanized monoclonal antibody targeting the p19 subunit of interleukin IL-23. Over the past few years, it has been the subject of clinical trials as a potential new treatment for inflammatory bowel diseases, including ulcerative colitis and Crohn's disease. Additionally, mirikizumab has been investigated in clinical trials as a potential treatment for plaque psoriasis. The results of clinical trials for mirikizumab in treating ulcerative colitis led to its approval in the European Union, the United States, Canada, and Japan for treating adult patients with moderately to severely active ulcerative colitis. Despite promising clinical trial results, mirikizumab has not yet been approved for the treatment of Crohn's disease. This review focuses on summarizing the findings from clinical trials of mirikizumab in the treatment of inflammatory bowel diseases. Information is sourced from scientific papers available on PubMed, by searching for "mirikizumab" and "IL-23" and published to March 2024, as well as from published results of clinical trials concerning mirikizumab.

引用

页码：178 / 185

页数：8

共 50 条

[41] Biologic targeting in the treatment of inflammatory bowel diseases
Bosani, Matteo
Ardizzone, Sandro
Porro, Gabriele Bianchi
BIOLOGICS-TARGETS & THERAPY, 2009, 3 : 77 - 97
[42] Inflammatory bowel diseases: Epidemiological features and treatment
Kurekci, Derya Deniz
Bektas, Ahmet
Ayyildiz, Talat
Goren, Ibrahim
Yildirim, Beytullah
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 478 - 478
[43] History of Inflammatory Bowel Diseases
Actis, Giovanni Clemente
Pellicano, Rinaldo
Fagoonee, Sharmila
Ribaldone, Davide Giuseppe
JOURNAL OF CLINICAL MEDICINE, 2019, 8 (11)
[44] Inflammatory Bowel Diseases and Spondyloarthropathies
Gionchetti, Paolo
Calabrese, Carlo
Rizzello, Fernando
JOURNAL OF RHEUMATOLOGY, 2015, 42 : 21 - 23
[45] Methotrexate for Inflammatory Bowel Diseases - New Developments
Herfarth, Hans H.
DIGESTIVE DISEASES, 2016, 34 (1-2) : 140 - 146
[46] Inflammatory bowel diseases: a new wave of therapy
Murthy, S
Flanigan, A
Osborne, BJ
Murthy, NS
EXPERT OPINION ON THERAPEUTIC PATENTS, 1998, 8 (07) : 785 - 818
[47] Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases
Nunez, Paulina
Quera, Rodrigo
Yarur, Andres J.
DRUGS, 2023, 83 (04) : 299 - 314
[48] VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
Haddley, K.
DRUGS OF TODAY, 2014, 50 (04) : 309 - 319
[49] Hit the Road JAK! The Role of New Oral Treatment in Inflammatory Bowel Disease
Garrido, Isabel
Lopes, Susana
Macedo, Guilherme
INFLAMMATORY BOWEL DISEASES, 2021, 27 (12) : 2010 - 2022
[50] New Insights into Inflammatory Bowel Diseases from Proteomic and Lipidomic Studies
Longo, Serena
Chieppa, Marcello
Cossa, Luca G.
Spinelli, Chiara C.
Greco, Marco
Maffia, Michele
Giudetti, Anna M.
PROTEOMES, 2020, 8 (03)

← 1 2 3 4 5 →